Natera (NTRA) Form 4 Filings

Natera, Inc. reported that Chief Financial Officer Michael Burkes Brophy received a grant of 10,051 Restricted Stock Units (RSUs) of common stock at no cost. The RSUs vest over four years, with 25% vesting on March 1, 2027 and the remainder in 12 equal quarterly installments. Each RSU converts into one share of common stock when it vests. Following this award, Brophy holds 62,171 shares of Natera common stock directly.

Natera, Inc. president of clinical diagnostics Solomon Moshkevich reported several open‑market sales of Natera common stock. On February 2 and 3, 2026, he sold blocks of shares at weighted average prices ranging from about $228.50 to $234.00 per share.

The Form 4 shows individual transactions between 16 and 1,639 shares each, leaving 137,847 shares beneficially owned directly after the final sale. Most sales were made under a pre‑arranged Rule 10b5‑1 trading plan, and one 1,639‑share sale was executed to cover tax withholding on vesting RSUs.

Natera, Inc. CEO and President Steven Leonard Chapman reported multiple stock sales in early February 2026. On February 2 and 3, he sold several blocks of Natera common stock at weighted average prices generally between $228.50 and $234.00 per share, in open-market transactions.

The filing states that most sales on February 2 were made under a Rule 10b5-1 trading plan adopted on December 11, 2023 and amended on December 2, 2024, which automates trading according to preset instructions. A separate February 3 sale of 4,725 shares at a weighted average price of $230.768 was made to cover tax withholding tied to vesting restricted stock units. After these transactions, Chapman directly owned 123,156 shares of Natera common stock.

Natera, Inc. chief financial officer Michael Burkes Brophy reported multiple stock sales on February 3, 2026. He sold 1,268 shares of common stock at $230.768 per share to cover tax withholding tied to restricted stock unit vesting. He also sold 700 shares at a weighted average price of $225.2479 and 4,971 shares at a weighted average price of $227.447 under a Rule 10b5-1 trading plan adopted in 2025. After these transactions, he directly held 52,120 Natera shares.

Natera, Inc. executive John Fesko, its President and Chief Business Officer, reported two sales of Natera common stock on February 3, 2026. He sold 1,179 shares at $230.768 and 2,415 shares at $231.14, both reported as direct holdings.

According to the filing, each sale was made to satisfy tax withholding and remittance obligations from vesting restricted stock units and was executed under written instructions intended to meet Rule 10b5-1(c) affirmative defense conditions. After these transactions, Fesko directly beneficially owns 178,081 shares of Natera common stock.

Natera, Inc. director and co-founder Sheena Jonathan reported a small sale of company stock. On February 3, 2026, she sold 435 shares of Natera common stock at $230.768 per share. The sale was made to cover tax withholding and remittance obligations tied to the vesting of restricted stock units and was executed under a written instruction intended to meet Rule 10b5-1(c) affirmative defense conditions in her January 31, 2025 stock unit agreement.

After this transaction, Jonathan directly holds 263,161 shares of Natera common stock. In addition, 21,782 shares are held by Caraluna 1 Trust and 21,782 shares are held by Caraluna 2 Trust for the benefit of trust beneficiaries, and she disclaims beneficial ownership of those trust-held shares.

Natera, Inc. officer Daniel Rabinowitz, the company’s Secretary and Chief Legal Officer, reported selling 1,334 shares of Natera common stock on February 3, 2026 at a price of $230.768 per share. After this transaction, he beneficially owned 223,813 shares directly.

The filing explains that the sale was carried out to cover tax withholding and remittance obligations arising from the vesting of restricted stock units (RSUs). It was executed under a written instruction intended to meet the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, indicating it was a pre-arranged, rule-compliant sale plan linked to prior equity grants.

Natera, Inc. reported that its President and Chief Business Officer, John Fesko, received an award of 6,135 restricted stock units (RSUs) of Natera common stock on January 30, 2026. These RSUs vested immediately upon issuance, and each RSU represents one share of common stock.

Following this equity grant, Fesko directly beneficially owns 181,675 shares of Natera common stock. The transaction was recorded at a price of $0.00 per share, reflecting a compensatory stock award rather than an open-market purchase.

Natera, Inc. director received 73 shares of common stock on January 30, 2026 through an award of restricted stock units (RSUs) granted in lieu of a $17,500 quarterly cash retainer for Board service.

The RSUs were fully vested at issuance, and each RSU converts into one share of Natera common stock. Following this grant, the director directly holds 5,389 shares of Natera common stock.

Natera, Inc. director Herm Rosenman reported a stock-based board fee. On 01/30/2026 he received 99 shares of Natera common stock through fully vested Restricted Stock Units granted in lieu of a quarterly board retainer of $23,750.

Each RSU represents one share of Natera common stock, so the grant directly increased his holdings. After this transaction, Rosenman beneficially owned 20,441 shares of Natera common stock held directly.

Natera, Inc. director Marcus Gail Boxer received an award of 91 restricted stock units on 01/30/2026 as part of his Board compensation. The RSUs were issued in lieu of quarterly retainer fees of $21,875 and were fully vested at issuance.

Each RSU represents a right to receive one share of Natera common stock. Following this grant, Boxer beneficially owned 5,853 shares of Natera common stock in direct ownership.

Natera director Rowan E. Chapman received equity compensation for board service. On 01/30/2026, Chapman was awarded 97 restricted stock units (RSUs) in lieu of a quarterly cash retainer of $23,125 for serving on Natera’s Board of Directors. The RSUs were fully vested at issuance, and each RSU represents one share of Natera common stock. Following this grant, Chapman directly beneficially owned 5,874 shares of Natera common stock.

Natera, Inc. director Roelof Botha received equity compensation for board service. On January 30, 2026, he was issued 112 Restricted Stock Units (RSUs) in lieu of a quarterly cash retainer of $26,875 for serving on Natera's Board of Directors. The RSUs were fully vested at issuance, and each RSU represents a right to receive one share of Natera common stock. Following this grant, Botha directly beneficially owned 2,540 shares of Natera common stock and indirectly beneficially owned 1,154,198 shares through estate planning vehicles.

Natera director Monica Bertagnolli received equity compensation instead of cash fees. On 01/30/2026 she was issued 70 Restricted Stock Units (RSUs) in lieu of a quarterly board retainer of $16,875. The RSUs were fully vested at issuance and each RSU equals one share of Natera common stock, bringing her directly held beneficial ownership to 5,291 shares.

Natera, Inc. director equity compensation filing: Director Roy D. Baynes received 70 shares of Natera common stock on 01/30/2026, reported as an acquisition under code "A". These shares were issued as Restricted Stock Units in lieu of a quarterly board retainer of $16,875.

The RSUs were fully vested at the time of issuance, and each RSU represents a right to receive one share of Natera common stock. Following this award, Baynes beneficially owns 18,429 shares of Natera common stock, held in direct ownership.

Natera, Inc. CEO and president Steven Leonard Chapman reported two small insider sales of common stock that were tied to restricted stock unit (RSU) vesting and related tax obligations. On January 27, 2026, he sold 2,322 shares at $240.5313, leaving 216,828 shares directly owned. On January 28, 2026, he sold 3,648 shares at $237.6624, leaving 213,180 shares directly owned. Both sales were executed under written instructions intended to satisfy Rule 10b5-1(c) affirmative defense conditions and were made to cover tax withholding and remittance obligations from RSU vesting.

Natera, Inc.’s chief financial officer Michael Burkes Brophy reported multiple sales of common stock on January 27–29, 2026. He sold blocks of 784, 1,237, 1,176, 991 and 876 shares at prices around $240–$230 per share. Footnotes state that part of the sales satisfied tax withholding obligations tied to vesting restricted stock units and relied on written instructions intended to qualify under Rule 10b5-1(c). Other sales were executed under a Rule 10b5-1 trading plan adopted on June 9, 2025 and modified on September 10, 2025. After these transactions, he directly held 59,059 common shares.

Natera, Inc. director and co-founder Sheena Jonathan reported small stock sales mainly to cover taxes on vesting RSUs. On January 27, 2026, she sold 291 shares of common stock at $240.5313 per share. On January 28, 2026, she sold an additional 191 shares at $237.6624 per share. After these transactions, she directly owned 263,596 shares of Natera common stock and indirectly held 21,782 shares in each of the Caraluna 1 Trust and Caraluna 2 Trust. The filing explains that both sales were executed to satisfy tax withholding and remittance obligations related to RSU vesting and were made under written instructions intended to meet Rule 10b5-1(c) affirmative defense conditions.

Natera, Inc. reported that its Secretary and Chief Legal Officer, Daniel Rabinowitz, sold small blocks of common stock to cover taxes on restricted stock unit (RSU) vesting. On January 27, 2026, he sold 886 shares at $240.5313 per share. On January 28, 2026, he sold an additional 1,000 shares at $237.6624 per share.

Both sales were made under written instructions intended to satisfy the affirmative defense conditions of Rule 10b5‑1(c) and were specifically to satisfy tax withholding and remittance obligations tied to previously granted RSUs. After these transactions, Rabinowitz directly owned 225,147 shares of Natera common stock.

Natera, Inc. executive Solomon Moshkevich, President of Clinical Diagnostics, reported small insider sales of common stock tied to RSU vesting. On January 27, 2026, he sold 1,013 shares at $240.5313, and on January 28, 2026 he sold 1,200 shares at $237.6624.

The filing states both sales were made to satisfy tax withholding and remittance obligations from restricted stock unit vesting, under a written instruction intended to meet Rule 10b5-1(c) affirmative defense conditions. After these transactions, he directly owns 142,486 shares of Natera common stock.

Natera, Inc. officer John Fesko reported small automatic sales of common stock tied to restricted stock unit vesting. On January 27, 2026, he sold 784 shares at $240.5313 each, and on January 28, 2026 he sold 928 shares at $237.6624 each. The transactions were made to satisfy tax withholding and remittance obligations under pre-set instructions intended to meet Rule 10b5-1(c) affirmative defense conditions. After these sales, he beneficially owned 175,540 shares of Natera common stock directly.

Natera, Inc. director and co-founder Sheena Jonathan reported multiple sales of Natera common stock on January 23, 2026 by two trusts associated with her. Caraluna 1 Trust sold an aggregate 750 shares in several trades at weighted average prices between about $242.02 and $245.19 per share, leaving it with holdings between 21,782 and 22,372 shares after each trade. Caraluna 2 Trust sold a total of 750 shares in similar transactions at weighted average prices ranging from $242.13 to $245.39 per share, ending with 21,782 shares after the last transaction. These sales were carried out under a Rule 10b5-1 trading plan adopted on June 7, 2024. Jonathan also reports 264,078 shares held directly. The trust-held shares are for the benefit of trust beneficiaries, and she disclaims beneficial ownership of those securities.

Natera, Inc. CEO and President Steven Leonard Chapman reported routine equity transactions involving company stock. On January 20, 2026, he exercised 3,386 Restricted Stock Units, each representing one share of Natera common stock, and received the same number of shares. That day he sold 71,932 shares of common stock at an average price of $234.7384 per share to cover tax withholding and remittance obligations related to RSU vesting, under a pre-set instruction intended to satisfy Rule 10b5‑1(c). On January 21, 2026, he sold an additional 1,590 shares of common stock at $235 per share, also to satisfy tax obligations tied to RSU vesting.

After these transactions, Chapman beneficially owned 219,150 shares of Natera common stock directly. The RSUs referenced vest over four years, with 25% having vested on January 20, 2023 and the remainder vesting in 12 equal quarterly installments thereafter.

Natera, Inc. CFO Michael Burkes Brophy reported multiple stock transactions tied to RSU vesting and a preset trading plan. On January 20, 2026, he sold 23,948 shares of common stock at an average price of $234.7384 per share and had 1,522 Restricted Stock Units convert into the same number of common shares at an exercise price of $0. On January 21, 2026, he sold 602 shares at $235 per share and 36,573 shares at an average price of $242.6685 per share. The filing states that certain sales were made to cover tax withholding obligations upon RSU vesting and that the reported sales were executed under a Rule 10b5-1 trading plan. Following these transactions, he directly owned 64,123 shares of Natera common stock.

Natera, Inc. co-founder and director Sheena Jonathan reported January 2026 stock transactions involving common shares and restricted stock units (RSUs). On January 20, 2026, she sold 2,981 common shares at a weighted average price of $234.7384, in a sale described as satisfying tax withholding obligations tied to RSU vesting, and 191 RSUs converted into the same number of common shares. On January 21, 2026, she reported additional sales of 93, 2,470, and 600 common shares at weighted average prices of $235, $234.1157, and $235.8183, including trades made under a Rule 10b5-1 trading plan adopted on June 7, 2024. Following these transactions, she directly held 264,078 common shares and indirectly held 22,532 common shares in each of two trusts named Caraluna 1 Trust and Caraluna 2 Trust.

Natera, Inc.’s Secretary and Chief Legal Officer Daniel Rabinowitz reported routine transactions in company stock tied to restricted stock unit (RSU) vesting. On January 20, 2026, he exercised 856 RSUs, each converting into one share of common stock, and sold 19,234 shares at $234.7384 per share to cover tax withholding and remittance obligations under a pre-set Rule 10b5-1 trading instruction. On January 21, 2026, he reported an additional tax-related sale of 438 shares at $235 per share under a similar instruction.

After these transactions, Rabinowitz directly owned 227,033 shares of Natera common stock. The RSUs referenced vest over four years, with 25% having vested on January 20, 2023 and the remaining units vesting in 12 equal quarterly installments thereafter.

Natera, Inc.January 20, 2026, he sold 23,205 shares of common stock at $234.7384 per share, leaving 144,992 shares beneficially owned directly after that transaction. On January 21, 2026, he sold an additional 293 shares at $235.00 per share, with 144,699 shares beneficially owned directly afterward.

The footnotes state that both sales were effected to satisfy tax withholding and remittance obligations arising from the vesting of restricted stock units granted on January 27, 2023 and January 28, 2022, under written instructions intended to meet the affirmative defense conditions of Rule 10b5‑1(c) under the Exchange Act.

Natera, Inc. insider John Fesko, the company’s President and Chief Business Officer, reported two sales of Natera common stock. On January 20, 2026, he sold 17,806 shares at an average price of $234.7384 per share. On January 21, 2026, he sold an additional 339 shares at $235 per share.

The filing explains that both transactions were made to cover tax withholding and remittance obligations arising from the vesting of Restricted Stock Units and were executed under written instructions intended to satisfy Rule 10b5-1(c) affirmative defense conditions. After these transactions, Fesko beneficially owns 177,252 shares of Natera common stock directly.

Natera, Inc.’s chief financial officer, Brophy Michael Burkes, reported the vesting of performance-based equity. On January 14, 2026, 59,596 shares of Natera common stock were acquired at a price of $0 per share upon the certification of a performance milestone under a restricted stock unit (RSU) award originally granted on January 27, 2023. The RSUs vest in tranches based on a mix of time-based service and business performance criteria. Following this vesting event, Burkes directly beneficially owns 123,722 shares of Natera common stock.

Natera, Inc. reported an insider equity award for its CEO and President, Steven Leonard Chapman. On January 14, 2026, 152,718 shares of Natera common stock were acquired at a price of $0 per share through the vesting of a performance-based Restricted Stock Unit (RSU) award. This award was originally granted on January 27, 2023 and vests in tranches when a mix of time-based and business performance milestones are achieved.

Following this vesting event, Chapman directly beneficially owned 289,286 shares of Natera common stock. The transaction reflects equity compensation tied to meeting a certified performance threshold rather than an open-market purchase.

Natera, Inc. reported an insider equity award event for John Fesko, its President and Chief Business Officer. On January 14, 2026, he acquired 44,698 shares of Natera common stock at $0 per share, reported as an acquisition of non-derivative securities. This came from a performance-based restricted stock unit (RSU) award granted on January 27, 2023, which vests in tranches when time-based and business performance milestones are achieved. The certification of one such performance milestone triggered this vesting. Following this transaction, Fesko beneficially owns 195,397 shares of Natera common stock directly.

Natera, Inc. executive Solomon Moshkevich reported an equity award tied to performance goals. On January 14, 2026, 44,698 shares of Natera common stock were acquired at $0 per share when a performance threshold under a previously granted performance-based restricted stock unit (RSU) award was certified.

The RSU grant, originally awarded on January 27, 2023, vests in tranches upon achieving milestones based on time and business performance criteria. Following this vesting event, Moshkevich directly beneficially owns 168,197 shares of Natera common stock.

Natera, Inc.’s Secretary and Chief Legal Officer, Daniel Rabinowitz, reported the vesting of 37,248 shares of Common Stock on January 14, 2026. These shares came from a performance-based Restricted Stock Unit award granted on January 27, 2023, which vests in tranches when time and business performance milestones are achieved.

After this zero-cost acquisition, Rabinowitz beneficially owns 245,849 shares of Natera Common Stock directly. The vesting followed certification that a specified performance threshold under the RSUs had been met.

Natera, Inc. director and co-founder Sheena Jonathan reported the vesting of 7,450 shares of Common Stock on January 14, 2026. These shares vested under a performance-based Restricted Stock Unit award granted on January 27, 2023, after a milestone tied to time and business performance criteria was certified. Following this vesting, she holds 270,031 shares of Common Stock directly. She also has indirect beneficial ownership of 22,532 shares held by Caraluna 1 Trust and 22,532 shares held by Caraluna 2 Trust.

A Natera, Inc. director and co‑founder reported recent changes in their holdings of the company’s common stock. On December 15, 2025, they donated 1,060 shares as a charitable contribution at a reported price of $0.

On December 17, 2025, they sold 1,592, 1,348 and 130 shares in separate transactions at weighted average prices of $226.5404, $227.4355 and $228.2831 per share, effected under a Rule 10b5‑1 trading plan adopted on December 11, 2024. After these transactions, the reporting person directly beneficially owned 222,966 shares, with an additional 23,282 shares held in each of two Caraluna trusts for beneficiaries, over which they disclaim beneficial ownership.

An officer of Natera, Inc. who serves as President, Clinical Diagnostics reported multiple equity transactions in December 2025. On 12/12/2025, the officer made a charitable gift of 180 common shares, exercised 8,876 and 13,500 stock options at an exercise price of $9.59 per share, and sold 4,692 shares at an average price of $230.7575 to cover the option exercise price and tax obligations. On 12/15/2025, the officer made an additional charitable gift of 115 shares. After these transactions, the officer directly owns 126,450 common shares and holds 5,125 stock options at $9.59 per share, which are fully exercisable and expire on 04/07/2026.

Natera, Inc. reported insider activity by a company director involving both equity awards and stock sales. On 10/31/2025, the director received 132 Restricted Stock Units (RSUs) in lieu of a $23,750 quarterly cash retainer for board service, and these RSUs were fully vested at issuance, with each RSU representing one share of common stock.

Following this grant, the director held 68,761 common shares directly. On 12/12/2025, the director sold several blocks of Natera common stock: 14,372 shares at a weighted average price of $226.6174, 21,910 shares at $227.3532, 11,987 shares at $228.4858, and 150 shares at $229.095, all in multiple trades within narrow price ranges. After these transactions, the director directly owned 20,342 Natera shares.

Natera, Inc. reported an insider transaction by an officer serving as its SEC. and Chief Legal Officer. On December 4, 2025, this officer exercised stock options to acquire 6,902 shares of Natera common stock at an exercise price of $19.68 per share, converting derivative securities into common stock.

Following the transaction, the officer directly beneficially owned 208,601 shares of Natera common stock. The filing also shows 5,598 remaining stock options with a $19.68 exercise price, expiring on March 21, 2029, and notes that the option shares are fully exercisable.

Natera, Inc. (NTRA) reported insider selling by a director on a Form 4. On November 24, 2025, estate planning vehicles associated with the reporting person sold multiple blocks of Natera common stock, each reported as open-market sales. The trades used weighted average prices, with individual transactions occurring in ranges from $228.70 to $239.07 per share.

After the reported sales, the director indirectly beneficially owned 1,154,198 shares of Natera common stock through estate planning vehicles. One footnote states this indirect position includes 4,411 shares transferred to an estate planning vehicle in a transaction exempt from Section 16. The pricing details are available in ranges, and the reporting person has undertaken to provide exact breakdowns of shares sold at each price upon request.

Natera, Inc. (NTRA) director and co‑founder reported open‑market sales of company stock. On 11/20/2025, the reporting person sold 10,000 shares of Natera common stock at a weighted average price of $225.0816 per share under a Rule 10b5‑1 trading plan adopted on December 11, 2024, and continued to hold 222,660 shares directly afterward.

On 11/21/2025, 2,000 shares were sold at a weighted average price of $230.0097 per share through the Caraluna 1 Trust and 2,000 shares were sold at a weighted average price of $230.0055 per share through the Caraluna 2 Trust, both under a separate Rule 10b5‑1 trading plan adopted on June 7, 2024, leaving 23,282 shares held in each trust. The shares in the trusts are held for the benefit of the trust beneficiaries, and the reporting person disclaims beneficial ownership of those securities.

Natera, Inc. director reports option exercises and share sales. A Natera director filed a Form 4 showing multiple transactions in Natera common stock on November 19 and 20, 2025. The director exercised stock options to acquire 5,112 shares at an exercise price of $40.93 on November 19, and then exercised options for 600 shares at $40.93 and 7,068 shares at $41.19 on November 20. On the same dates, the director sold several blocks of Natera common stock in open market transactions at weighted average prices ranging from about $213.18 to $224.92 per share, under a Rule 10b5-1 trading plan adopted on August 20, 2025. Following these transactions, the director reported owning 18,359 shares of Natera common stock directly and no remaining options in the reported option grants.

Natera (NTRA) director and co‑founder reported open‑market sales of common stock under Rule 10b5‑1 plans. On 11/07/2025, multiple sales were executed at weighted average prices between $190.00 and $198.38, leaving 232,660 shares held directly after the transactions. On 11/11/2025, additional sales by the Caraluna 1 Trust and Caraluna 2 Trust occurred at weighted averages between $206.68 and $209.29; following these, each trust showed 25,282 shares. The reporting person disclaims beneficial ownership of the trust‑held shares.

Natera, Inc. (NTRA) — Form 4 insider transaction

A reporting person who is a director and co‑founder disclosed open‑market sales of Natera common stock on 11/03/2025 under a Rule 10b5‑1 trading plan adopted on June 7, 2024. Two separate sales of 2,000 shares each were executed through trusts, for a total of 4,000 shares. One sale had a weighted average price of $200.1368 with trade prices ranging from $200.00 to $200.30; the other was reported at $200.00 per share.

Following the transactions, the filing lists 235,730 shares beneficially owned directly. The trusts are held for the benefit of their beneficiaries, and the reporting person disclaims beneficial ownership of those securities.

Natera, Inc. (NTRA) reported a Form 4 showing that its officer, President, Clinical Diagnostics, executed open‑market sales totaling 3,000 shares of common stock on 11/03/2025 under a Rule 10b5‑1 trading plan adopted on November 26, 2024.

The sales occurred in three tranches: 1,450 shares at a weighted average price of $198.026, 1,450 shares at $199.1023, and 100 shares at $199.74. Following these transactions, the reporting person beneficially owned 112,061 shares, held directly.

Natera (NTRA) reported an insider equity award. A director acquired 97 Restricted Stock Units on 10/31/2025, issued in lieu of a quarterly board retainer of $17,500. The RSUs were fully vested at issuance, and each RSU represents one share of common stock. Following this transaction, the director beneficially owns 5,316 shares directly.

Natera, Inc. disclosed a Form 4 reporting that a director acquired 128 shares through fully vested RSUs issued in lieu of a $23,125 quarterly board retainer on 10/31/2025. Each RSU represents one share of common stock.

After this transaction, the reporting person beneficially owned 6,143 shares held directly.

Natera (NTRA) disclosed a Form 4 for a board member showing an equity award on 10/31/2025. The director received 149 Restricted Stock Units (RSUs) issued in lieu of a $26,875 quarterly board retainer, and the RSUs were fully vested at grant.

After this transaction, the reporting person beneficially owned 6,839 shares directly and 1,224,787 shares indirectly through estate planning vehicles.

Natera, Inc. (NTRA) reported a routine insider transaction. A director filed a Form 4 showing an award of 93 Restricted Stock Units (RSUs) on 10/31/2025 in lieu of quarterly retainer fees of $16,875 for board service. The filing states the RSUs were fully vested at issuance, and each RSU represents the right to receive one share of common stock. Following this transaction, the reporting person beneficially owned 5,221 shares, held directly.

Natera, Inc. (NTRA) reported an insider equity award. On 10/31/2025, a director received 93 restricted stock units (RSUs) in lieu of a quarterly board retainer of $16,875. The filing states these RSUs were fully vested at issuance, and each RSU represents the right to receive one share of Natera common stock.

Following this transaction, the reporting person beneficially owned 18,359 shares, held directly.